Burlington, Massachusetts-based Coronado Biosciences, Inc., (CNDO), is a clinical stage biopharmaceutical company that develops immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. Coronado was founded in 2006.
This 230M market cap company's lead pharmaceutical product candidates are:
- TSO or CNDO-201, a biologic comprising Trichuris suis ovathe, the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, type 1 diabetes, and rheumatoid arthritis; and
- CNDO-109, a biologic that activates the immune system's natural killer (NK) cells to target and kill cancer cells, for the treatment of acute myeloid leukemia (AML) and myeloid myeloma.
TSO (Trichuris suis...
Only subscribers can access this article, which is part of the PRO research library covering 3,768 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: